DURECT Stock Price, News & Analysis (NASDAQ:DRRX)

$1.12 +0.03 (+2.75 %)
(As of 02/19/2018 10:42 AM ET)
Previous Close$1.09
Today's Range$1.07 - $1.14
52-Week Range$0.74 - $2.17
Volume241,700 shs
Average Volume617,106 shs
Market Capitalization$166.37 million
P/E RatioN/A
Dividend YieldN/A
Beta1.79

About DURECT (NASDAQ:DRRX)

DURECT logoDurect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company's ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.

Receive DRRX News and Ratings via Email

Sign-up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DRRX
CUSIPN/A
Phone408-777-1417

Debt

Debt-to-Equity Ratio1.46%
Current Ratio1.67%
Quick Ratio1.57%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$14.02 million
Price / Sales11.87
Cash FlowN/A
Price / CashN/A
Book Value$0.06 per share
Price / Book18.67

Profitability

Trailing EPS($0.15)
Net Income$-34,500,000.00
Net Margins-62.57%
Return on Equity-419.65%
Return on Assets-45.77%

Miscellaneous

Employees98
Outstanding Shares148,550,000

DURECT (NASDAQ:DRRX) Frequently Asked Questions

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) released its quarterly earnings results on Wednesday, November, 1st. The specialty pharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.05) by $0.09. The specialty pharmaceutical company earned $20.75 million during the quarter, compared to the consensus estimate of $5.09 million. DURECT had a negative return on equity of 419.65% and a negative net margin of 62.57%. View DURECT's Earnings History.

When will DURECT make its next earnings announcement?

DURECT is scheduled to release their next quarterly earnings announcement on Tuesday, March, 13th 2018. View Earnings Estimates for DURECT.

Where is DURECT's stock going? Where will DURECT's stock price be in 2018?

3 equities research analysts have issued 12 month target prices for DURECT's stock. Their forecasts range from $2.00 to $3.00. On average, they anticipate DURECT's share price to reach $2.67 in the next twelve months. View Analyst Ratings for DURECT.

Who are some of DURECT's key competitors?

Who are DURECT's key executives?

DURECT's management team includes the folowing people:

  • Felix D Theeuwes, Chairman, Chief Scientific Officer (Age 78)
  • James E. Brown DVM, President, Chief Executive Officer and Director (Age 58)
  • Matthew J. Hogan, Chief Financial Officer (Age 55)
  • Judy R. Joice, Senior Vice President - Operations and Corporate Quality Assurance (Age 58)
  • Myriam Theeuwes, Senior Vice President - Clinical Development
  • David R. Hoffmann, Lead Independent Director (Age 70)
  • Simon X. Benito, Independent Director (Age 72)
  • Terrence F. Blaschke M.D., Independent Director (Age 72)
  • Armand P. Neukermans Ph.D., Independent Director (Age 74)
  • Jon S. Saxe J.D., Independent Director (Age 80)

Who owns DURECT stock?

DURECT's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.56%), Ingalls & Snyder LLC (5.79%), Tocqueville Asset Management L.P. (0.82%), Gagnon Securities LLC (0.77%), Renaissance Technologies LLC (0.46%) and Wells Fargo & Company MN (0.32%). Company insiders that own DURECT stock include April Fund LP 21, Armand Neukermans, Dave Hoffmann, Felix Theeuwes and James E Brown. View Institutional Ownership Trends for DURECT.

Who sold DURECT stock? Who is selling DURECT stock?

DURECT's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Tocqueville Asset Management L.P., Deutsche Bank AG and Gagnon Securities LLC. View Insider Buying and Selling for DURECT.

Who bought DURECT stock? Who is buying DURECT stock?

DURECT's stock was acquired by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Renaissance Technologies LLC, BlackRock Inc., SG Americas Securities LLC, Algert Global LLC and Wells Fargo & Company MN. Company insiders that have bought DURECT stock in the last two years include April Fund LP 21, Armand Neukermans, Dave Hoffmann, Felix Theeuwes and James E Brown. View Insider Buying and Selling for DURECT.

How do I buy DURECT stock?

Shares of DURECT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DURECT's stock price today?

One share of DURECT stock can currently be purchased for approximately $1.12.

How big of a company is DURECT?

DURECT has a market capitalization of $166.37 million and generates $14.02 million in revenue each year. The specialty pharmaceutical company earns $-34,500,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. DURECT employs 98 workers across the globe.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417.


MarketBeat Community Rating for DURECT (DRRX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  142 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  228
MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

DURECT (NASDAQ:DRRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.332.332.333.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.67$2.67$2.67$3.17
Price Target Upside: 234.46% upside234.46% upside234.46% upside99.16% upside

DURECT (NASDAQ:DRRX) Consensus Price Target History

Price Target History for DURECT (NASDAQ:DRRX)

DURECT (NASDAQ:DRRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/2/2017HC WainwrightReiterated RatingHoldN/AView Rating Details
10/20/2017LaidlawLower Price TargetBuy -> Buy$3.00 -> $2.00N/AView Rating Details
10/20/2017Stifel NicolausDowngradeBuy -> HoldN/AView Rating Details
9/27/2016Rodman & RenshawReiterated RatingBuy$4.00 -> $3.50N/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

DURECT (NASDAQ:DRRX) Earnings History and Estimates Chart

Earnings by Quarter for DURECT (NASDAQ:DRRX)

DURECT (NASDAQ DRRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018($0.06)N/AView Earnings Details
11/1/2017Q3 2017($0.05)$0.04$5.09 million$20.75 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.05)($0.07)$5.17 million$4.32 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.06)($0.06)$3.60 million$4.57 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.06)($0.06)$3.03 million$3.52 millionViewN/AView Earnings Details
10/31/2016Q316($0.07)($0.06)$3.72 million$37.00 millionViewListenView Earnings Details
8/1/2016Q216($0.06)($0.07)$3.69 million$3.20 millionViewListenView Earnings Details
5/5/2016Q116($0.06)($0.06)$4.09 million$3.60 millionViewListenView Earnings Details
2/29/2016Q415($0.06)($0.05)$4.83 million$5.20 millionViewListenView Earnings Details
11/2/2015Q315($0.05)($0.05)$5.08 million$4.70 millionViewListenView Earnings Details
8/3/2015Q215($0.06)($0.05)$5.01 million$4.40 millionViewListenView Earnings Details
4/30/2015Q115($0.06)($0.04)$4.82 million$4.77 millionViewListenView Earnings Details
3/2/2015Q414($0.05)($0.05)$4.32 million$4.30 millionViewListenView Earnings Details
11/3/2014Q3($0.05)($0.06)$4.10 million$4.26 millionViewListenView Earnings Details
8/7/2014Q2($0.05)($0.05)$3.90 million$4.58 millionViewListenView Earnings Details
5/1/2014Q1($0.05)($0.03)$4.12 million$6.30 millionViewListenView Earnings Details
2/27/2014Q4($0.06)($0.05)$2.79 million$4.30 millionViewListenView Earnings Details
11/4/2013Q3 2013($0.06)($0.06)$3.57 million$2.97 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.05)($0.05)$3.42 million$3.92 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.06)($0.05)$3.78 million$4.15 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.06)($0.06)ViewN/AView Earnings Details
11/5/2012Q3 2012($0.05)($0.05)ViewN/AView Earnings Details
8/6/2012Q2 2012($0.04)($0.05)ViewN/AView Earnings Details
5/3/2012Q1 2012($0.07)$0.35ViewN/AView Earnings Details
3/1/2012Q4 2011($0.08)($0.02)ViewN/AView Earnings Details
11/3/2011Q3 2011($0.05)($0.06)ViewN/AView Earnings Details
8/4/2011Q2 2011($0.07)($0.06)ViewN/AView Earnings Details
5/5/2011Q1 2011($0.06)($0.07)ViewN/AView Earnings Details
3/2/2011Q4 2010($0.06)($0.06)ViewN/AView Earnings Details
11/3/2010Q3 2010($0.06)($0.05)ViewN/AView Earnings Details
8/4/2010Q2 2010($0.08)($0.07)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.09)($0.08)ViewN/AView Earnings Details
2/24/2010Q4 2009($0.09)($0.10)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.09)($0.07)ViewN/AView Earnings Details
8/3/2009Q2 2009($0.10)($0.09)ViewN/AView Earnings Details
5/6/2009Q1 2009($0.08)($0.11)ViewN/AView Earnings Details
2/9/2009Q4 2008($0.10)($0.07)ViewN/AView Earnings Details
11/3/2008Q3 2008($0.09)($0.11)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.10)($0.11)ViewN/AView Earnings Details
5/7/2008Q1 2008($0.10)($0.11)ViewN/AView Earnings Details
2/5/2008Q4 2007($0.10)($0.10)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

DURECT (NASDAQ:DRRX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.14 EPS
Next Year EPS Consensus Estimate: $-0.17 EPS

Dividends

Dividend History for DURECT (NASDAQ:DRRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

DURECT (NASDAQ DRRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.30%
Institutional Ownership Percentage: 46.84%
Insider Trades by Quarter for DURECT (NASDAQ:DRRX)
Institutional Ownership by Quarter for DURECT (NASDAQ:DRRX)

DURECT (NASDAQ DRRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/3/2016April Fund L.P. 21Major ShareholderBuy95,000$1.16$110,200.00View SEC Filing  
9/26/2016April Fund L.P. 21Major ShareholderBuy2,500,000$1.15$2,875,000.00View SEC Filing  
4/26/2016April Fund L.P. 21Major ShareholderBuy5,500,000$1.25$6,875,000.00View SEC Filing  
4/26/2016Dave HoffmannDirectorBuy200,000$1.25$250,000.0025,000View SEC Filing  
4/26/2016Felix TheeuwesChairmanBuy160,000$1.25$200,000.00View SEC Filing  
3/14/2016Armand NeukermansDirectorBuy18,000$1.39$25,020.001,250View SEC Filing  
3/14/2016Felix TheeuwesChairmanBuy70,000$1.41$98,700.00View SEC Filing  
3/10/2016James E BrownCEOBuy20,000$1.33$26,600.001,764,530View SEC Filing  
1/11/2016April Fund Lp 21Major ShareholderBuy300,100$1.37$411,137.00View SEC Filing  
9/29/2015April Fund Ltd 21Major ShareholderBuy952,249$1.79$1,704,525.71View SEC Filing  
3/10/2015Simon X BenitoDirectorBuy40,000$1.81$72,400.00View SEC Filing  
3/9/2015Felix TheeuwesChairmanBuy225,600$1.65$372,240.00View SEC Filing  
3/6/2015Felix TheeuwesChairmanBuy380,000$1.57$596,600.00View SEC Filing  
11/21/2014Felix TheeuwesChairmanBuy72,700$1.00$72,700.00View SEC Filing  
11/20/2014Felix TheeuwesChairmanBuy136,015$0.92$125,133.80View SEC Filing  
11/8/2013Felix TheeuwesChairmanBuy714,285$1.40$999,999.00View SEC Filing  
9/10/2013Felix TheeuwesChairmanBuy75,000$1.20$90,000.00View SEC Filing  
9/9/2013Felix TheeuwesChairmanBuy25,000$1.15$28,750.00View SEC Filing  
6/4/2013James E BrownCEOBuy30,000$0.80$24,000.00View SEC Filing  
12/12/2012Jon S SaxeDirectorBuy15,000$0.91$13,650.00View SEC Filing  
11/14/2012Felix TheeuwesChairmanBuy100,000$1.01$101,000.00View SEC Filing  
8/28/2012Jon S SaxeDirectorBuy7,810$0.97$7,575.70View SEC Filing  
8/23/2012Jon S SaxeDirectorBuy5,000$1.00$5,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

DURECT (NASDAQ DRRX) News Headlines

Source:
DateHeadline
DURECT Co. (DRRX) Expected to Post Quarterly Sales of $4.60 MillionDURECT Co. (DRRX) Expected to Post Quarterly Sales of $4.60 Million
www.americanbankingnews.com - February 17 at 6:24 AM
DURECT Announces Resubmission of REMOXY® ER New Drug Application by its licensee, Pain TherapeuticsDURECT Announces Resubmission of REMOXY® ER New Drug Application by its licensee, Pain Therapeutics
finance.yahoo.com - February 14 at 9:49 AM
DURECT (DRRX) & Adaptimmune Therapeutics (ADAP) Critical ContrastDURECT (DRRX) & Adaptimmune Therapeutics (ADAP) Critical Contrast
www.americanbankingnews.com - February 8 at 1:18 AM
Zacks: Analysts Expect DURECT Co. (DRRX) to Post -$0.05 EPSZacks: Analysts Expect DURECT Co. (DRRX) to Post -$0.05 EPS
www.americanbankingnews.com - January 29 at 5:12 PM
Contrasting DURECT (DRRX) & KemPharm (KMPH)Contrasting DURECT (DRRX) & KemPharm (KMPH)
www.americanbankingnews.com - January 28 at 7:18 AM
$4.60 Million in Sales Expected for DURECT Co. (DRRX) This Quarter$4.60 Million in Sales Expected for DURECT Co. (DRRX) This Quarter
www.americanbankingnews.com - January 14 at 4:54 AM
 Brokerages Anticipate DURECT Co. (DRRX) to Announce -$0.05 EPS Brokerages Anticipate DURECT Co. (DRRX) to Announce -$0.05 EPS
www.americanbankingnews.com - January 12 at 7:34 PM
DURECT (DRRX) Upgraded to "Sell" at ValuEngineDURECT (DRRX) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - January 10 at 1:38 PM
Stocks Turning In Another Lackluster Performance - US CommentaryStocks Turning In Another Lackluster Performance - US Commentary
www.morningstar.co.uk - January 9 at 5:23 PM
-$0.05 Earnings Per Share Expected for DURECT Co. (DRRX) This Quarter-$0.05 Earnings Per Share Expected for DURECT Co. (DRRX) This Quarter
www.americanbankingnews.com - December 27 at 5:32 AM
ETFs with exposure to DURECT Corp. : December 11, 2017ETFs with exposure to DURECT Corp. : December 11, 2017
finance.yahoo.com - December 11 at 5:30 PM
 Brokerages Anticipate DURECT Corporation (DRRX) Will Post Quarterly Sales of $4.60 Million Brokerages Anticipate DURECT Corporation (DRRX) Will Post Quarterly Sales of $4.60 Million
www.americanbankingnews.com - December 11 at 9:50 AM
DURECT Corporation (DRRX) Expected to Announce Earnings of -$0.05 Per ShareDURECT Corporation (DRRX) Expected to Announce Earnings of -$0.05 Per Share
www.americanbankingnews.com - December 9 at 5:26 PM
DURECT Corporation (DRRX) Expected to Announce Quarterly Sales of $4.60 MillionDURECT Corporation (DRRX) Expected to Announce Quarterly Sales of $4.60 Million
www.americanbankingnews.com - November 23 at 4:52 AM
Zacks: Analysts Expect DURECT Corporation (DRRX) Will Announce Earnings of -$0.05 Per ShareZacks: Analysts Expect DURECT Corporation (DRRX) Will Announce Earnings of -$0.05 Per Share
www.americanbankingnews.com - November 21 at 5:20 PM
The Stock Market Cycle And Implications For Medical Stock InvestingThe Stock Market Cycle And Implications For Medical Stock Investing
seekingalpha.com - November 14 at 6:27 PM
Financial Survey: MacroGenics (MGNX) and DURECT Corporation (DRRX)Financial Survey: MacroGenics (MGNX) and DURECT Corporation (DRRX)
www.americanbankingnews.com - November 13 at 3:59 PM
DURECT Corporation (DRRX) Sees Large Increase in Short InterestDURECT Corporation (DRRX) Sees Large Increase in Short Interest
www.americanbankingnews.com - November 13 at 3:34 AM
DURECT Corp. :DRRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017DURECT Corp. :DRRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
finance.yahoo.com - November 10 at 10:46 AM
DURECT Corporation (DRRX) to Post FY2017 Earnings of ($0.13) Per Share, Zacks Investment Research ForecastsDURECT Corporation (DRRX) to Post FY2017 Earnings of ($0.13) Per Share, Zacks Investment Research Forecasts
www.americanbankingnews.com - November 6 at 6:14 AM
$4.72 Million in Sales Expected for DURECT Corporation (DRRX) This Quarter$4.72 Million in Sales Expected for DURECT Corporation (DRRX) This Quarter
www.americanbankingnews.com - November 3 at 6:08 AM
DRRX: Focus will be Shifted to DUR-928 ProgramsDRRX: Focus will be Shifted to DUR-928 Programs
finance.yahoo.com - November 2 at 7:04 PM
DURECT Corp (DRRX) Tops Q3 EPS by 10c - StreetInsider.comDURECT Corp (DRRX) Tops Q3 EPS by 10c - StreetInsider.com
www.streetinsider.com - November 2 at 5:07 AM
Edited Transcript of DRRX earnings conference call or presentation 1-Nov-17 8:30pm GMTEdited Transcript of DRRX earnings conference call or presentation 1-Nov-17 8:30pm GMT
finance.yahoo.com - November 2 at 5:07 AM
DURECTs (DRRX) CEO James Brown on Q3 2017 Results - Earnings Call TranscriptDURECT's (DRRX) CEO James Brown on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 2 at 12:04 AM
DURECT Corporation (DRRX) Announces Quarterly  Earnings Results, Beats Estimates By $0.10 EPSDURECT Corporation (DRRX) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS
www.americanbankingnews.com - November 1 at 8:34 PM
DURECT Corporation Announces Third Quarter 2017 Financial Results and Provides Corporate UpdateDURECT Corporation Announces Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 1 at 7:01 PM
Durect tops Street 3Q forecastsDurect tops Street 3Q forecasts
finance.yahoo.com - November 1 at 7:01 PM
FY2018 EPS Estimates for DURECT Corporation Reduced by Analyst (DRRX)FY2018 EPS Estimates for DURECT Corporation Reduced by Analyst (DRRX)
www.americanbankingnews.com - October 27 at 5:48 PM
DURECT Corporation Invites You to Join its Third Quarter 2017 ... - PR Newswire (press release)DURECT Corporation Invites You to Join its Third Quarter 2017 ... - PR Newswire (press release)
www.prnewswire.com - October 26 at 11:57 PM
DURECT Corporation Invites You to Join its Third Quarter 2017 Earnings Conference CallDURECT Corporation Invites You to Join its Third Quarter 2017 Earnings Conference Call
finance.yahoo.com - October 26 at 6:54 PM
ETFs with exposure to DURECT Corp. : October 26, 2017ETFs with exposure to DURECT Corp. : October 26, 2017
finance.yahoo.com - October 26 at 1:51 PM
Durect Takes A Beating On Pain Drug, Still holds Enormous Potential Value - Seeking AlphaDurect Takes A Beating On Pain Drug, Still holds Enormous Potential Value - Seeking Alpha
seekingalpha.com - October 23 at 6:29 PM
DURECT Co. (DRRX) to Release Quarterly Earnings on MondayDURECT Co. (DRRX) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - October 23 at 10:56 AM
UPDATE: H.C. Wainwright Downgrades Durect Corp (DRRX) to NeutralUPDATE: H.C. Wainwright Downgrades Durect Corp (DRRX) to Neutral
www.streetinsider.com - October 21 at 5:20 PM
DURECT Corporation (DRRX) Cut to Hold at Stifel NicolausDURECT Corporation (DRRX) Cut to Hold at Stifel Nicolaus
www.americanbankingnews.com - October 21 at 3:34 PM
HC Wainwright Lowers DURECT Corporation (DRRX) to NeutralHC Wainwright Lowers DURECT Corporation (DRRX) to Neutral
www.americanbankingnews.com - October 21 at 2:58 PM
DURECT Corporation (DRRX) Cut to "Strong Sell" at ValuEngineDURECT Corporation (DRRX) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - October 21 at 10:40 AM
Mid-Day Market Update: Dow Surges Over 100 Points; DURECT ... - NasdaqMid-Day Market Update: Dow Surges Over 100 Points; DURECT ... - Nasdaq
www.nasdaq.com - October 21 at 5:36 AM
DURECTs pain med Posimir flunks late-stage study; shares plummet 55% premarket - Seeking AlphaDURECT's pain med Posimir flunks late-stage study; shares plummet 55% premarket - Seeking Alpha
seekingalpha.com - October 21 at 5:36 AM
UPDATE: Durect Corp (DRRX) PT Lowered to $2 at Laidlaw - StreetInsider.comUPDATE: Durect Corp (DRRX) PT Lowered to $2 at Laidlaw - StreetInsider.com
www.streetinsider.com - October 21 at 5:36 AM
Pre-Open Stock Movers 10/20: (SKX) (TEAM) (QURE) Higher; (DRRX) (NCR) (CELG) (GE) Lower (more...)Pre-Open Stock Movers 10/20: (SKX) (TEAM) (QURE) Higher; (DRRX) (NCR) (CELG) (GE) Lower (more...)
www.streetinsider.com - October 20 at 7:31 PM
DURECT Corporation (DRRX) Shares Collapse – Here’s WhyDURECT Corporation (DRRX) Shares Collapse – Here’s Why
finance.yahoo.com - October 20 at 7:31 PM
Laidlaw Trims DURECT Corporation (DRRX) Target Price to $2.00Laidlaw Trims DURECT Corporation (DRRX) Target Price to $2.00
www.americanbankingnews.com - October 20 at 10:12 AM
DURECT Corp (DRRX) PERSIST Phase 3 Trial of POSIMIR Misses ... - StreetInsider.comDURECT Corp (DRRX) PERSIST Phase 3 Trial of POSIMIR Misses ... - StreetInsider.com
www.streetinsider.com - October 19 at 11:38 PM
DURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy EndpointDURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy Endpoint
finance.yahoo.com - October 19 at 6:36 PM
ETFs with exposure to DURECT Corp. : October 16, 2017ETFs with exposure to DURECT Corp. : October 16, 2017
finance.yahoo.com - October 16 at 6:41 PM
Zacks: Brokerages Anticipate DURECT Corporation (DRRX) Will Announce Quarterly Sales of $5.09 MillionZacks: Brokerages Anticipate DURECT Corporation (DRRX) Will Announce Quarterly Sales of $5.09 Million
www.americanbankingnews.com - October 15 at 8:06 AM
$5.09 Million in Sales Expected for DURECT Corporation (DRRX) This Quarter$5.09 Million in Sales Expected for DURECT Corporation (DRRX) This Quarter
www.americanbankingnews.com - October 12 at 10:54 AM
Zacks: Brokerages Expect DURECT Corporation (DRRX) Will Post Earnings of -$0.05 Per ShareZacks: Brokerages Expect DURECT Corporation (DRRX) Will Post Earnings of -$0.05 Per Share
www.americanbankingnews.com - October 10 at 8:20 PM

SEC Filings

DURECT (NASDAQ:DRRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

DURECT (NASDAQ:DRRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

DURECT (NASDAQ DRRX) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.